Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours?

Biochem Pharmacol. 2021 Dec:194:114797. doi: 10.1016/j.bcp.2021.114797. Epub 2021 Oct 19.

Abstract

In children and young adults, primary malignant bone tumours are mainly composed of osteosarcoma and Ewing's sarcoma. Despite advances in treatments, nearly 40% of patients succumb to these diseases. In particular, the clinical outcome of metastatic osteosarcoma or Ewing's sarcoma remains poor, with less than 30% of patients who develop metastases surviving five years after initial diagnosis. Over the last decade, the cancer research community has shown considerable interest in the processes of protein ubiquitination and deubiquitination. In particular, a growing number of studies show the relevance to target the ubiquitin-specific protease (USP) family in various cancers. This review provides an update on the current knowledge regarding the implication of these USPs in the progression of bone sarcoma: osteosarcoma and Ewing's sarcoma.

Keywords: Cancer development; Ewing’s sarcoma; Osteosarcoma; Therapeutic targets; Ubiquitin-specific proteases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / enzymology*
  • Child
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Humans
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / enzymology*
  • Transforming Growth Factor beta / antagonists & inhibitors
  • Transforming Growth Factor beta / metabolism
  • Ubiquitin-Specific Proteases / antagonists & inhibitors
  • Ubiquitin-Specific Proteases / metabolism*
  • Ubiquitination / drug effects
  • Ubiquitination / physiology

Substances

  • Antineoplastic Agents
  • Transforming Growth Factor beta
  • Ubiquitin-Specific Proteases